Modality
Fusion Protein
MOA
JAK1/2i
Target
Menin
Pathway
RNA Splicing
ADPKDFabryMS
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
Mar 2017
→ Oct 2027
Phase 1Current
NCT03957704
284 pts·MS
2023-06→2027-10·Completed
NCT08045492
668 pts·ADPKD
2017-03→2026-04·Terminated
952 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-022d awayPh2 Data· ADPKD
2027-10-101.5y awayPh2 Data· MS
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Termina…
P1/2
Complet…
Catalysts
Ph2 Data
2026-04-02 · 2d away
ADPKD
Ph2 Data
2027-10-10 · 1.5y away
MS
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03957704 | Phase 1/2 | MS | Completed | 284 | EFS |
| NCT08045492 | Phase 1/2 | ADPKD | Terminated | 668 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| Cevimavacamten | Denali | NDA/BLA | Menin | |
| Sovacagene | Relay Therapeutics | Phase 1/2 | Menin |